miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1 - PubMed (original) (raw)

. 2011 Apr;126(3):565-75.

doi: 10.1007/s10549-010-0954-4. Epub 2010 May 27.

Affiliations

• PMID: 20505989
• DOI: 10.1007/s10549-010-0954-4

miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1

Hongling Li et al. Breast Cancer Res Treat. 2011 Apr.

Abstract

MicroRNAs have been implicated in regulating diverse cellular pathways. Emerging evidence indicate that the miR-17-92 cluster may have a causal role in breast cancer tumorigenesis as a novel class of oncogenes, but the role of these miRNAs in breast cancer invasion and migration remains unexplored. The aims of this study were to verify the effect of miR-17-5p (an important member of the miR-17-92 cluster) on the invasive and migratory ability of breast cancer cells. The matching of miR-17-5p and HMG box-containing protein 1 (HBP1) was predicted by TargetScan and confirmed by DNA constructs and luciferase target assay. The expression levels of miR-17-5p and its candidate target-HBP1 in MCF7 and MDA-MB-231 breast cancer cells were measured by real-time PCR and western blotting. Effects of miR-17-5p in cell cycle progression, proliferation, invasion and migration were evaluated by flow cytometry assay, 3-(4,-dimethy -lthiazol-2-yl)-2,-diphenyl -tetrazoliumbromide assay, soft-agar colony formation assay, and transwell invasive and migratory assay, respectively. The results showed that miR-17-5p was highly expressed in high-invasive MDA-MB-231 breast cancer cells but not in low-invasive MCF-7 breast cancer cells. Over-expression of miR-17-5p in MCF-7 cells rendered them the invasive and migratory abilities by targeting HBP1/β-catenin pathway. On the other hand, down-regulation of endogenous miR-17-5p suppressed the migration and invasion of MDA-MB-231 cells in vitro. These findings suggest that miR-17-5p plays an important role in breast cancer cell invasion and migration by suppressing HBP1 and subsequent activation of Wnt/β-catenin.

PubMed Disclaimer

Similar articles

• The HMG box transcription factor HBP1: a cell cycle inhibitor at the crossroads of cancer signaling pathways.
  Bollaert E, de Rocca Serra A, Demoulin JB. Bollaert E, et al. Cell Mol Life Sci. 2019 Apr;76(8):1529-1539. doi: 10.1007/s00018-019-03012-9. Epub 2019 Jan 25. Cell Mol Life Sci. 2019. PMID: 30683982 Free PMC article. Review.
• Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.
  Shen Y, Ye YF, Ruan LW, Bao L, Wu MW, Zhou Y. Shen Y, et al. Genet Mol Res. 2017 Feb 23;16(1). doi: 10.4238/gmr16019479. Genet Mol Res. 2017. PMID: 28252173
• MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.
  Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, Karimipoor M, Soleimani M. Mohammadi-Yeganeh S, et al. Tumour Biol. 2016 Jul;37(7):8993-9000. doi: 10.1007/s13277-015-4513-9. Epub 2016 Jan 12. Tumour Biol. 2016. PMID: 26758430
• MicroRNA-205-5p inhibits the growth and migration of breast cancer through targeting Wnt/β-catenin co-receptor LRP6 and interacting with lncRNAs.
  Mohamed SH, Kamal MM, Reda AM, Mesbah NM, Abo-Elmatty DM, Abdel-Hamed AR. Mohamed SH, et al. Mol Cell Biochem. 2024 Oct 26. doi: 10.1007/s11010-024-05136-4. Online ahead of print. Mol Cell Biochem. 2024. PMID: 39461917 Review.

Cited by

• Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs.
  Li X, Gao L, Cui Q, Gary BD, Dyess DL, Taylor W, Shevde LA, Samant RS, Dean-Colomb W, Piazza GA, Xi Y. Li X, et al. Oncogene. 2012 Nov 29;31(48):4979-86. doi: 10.1038/onc.2011.655. Epub 2012 Jan 30. Oncogene. 2012. PMID: 22286762 Free PMC article.
• Metastamirs: a stepping stone towards improved cancer management.
  White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. White NM, et al. Nat Rev Clin Oncol. 2011 Feb;8(2):75-84. doi: 10.1038/nrclinonc.2010.173. Epub 2010 Nov 2. Nat Rev Clin Oncol. 2011. PMID: 21045789 Review.
• The HMG box transcription factor HBP1: a cell cycle inhibitor at the crossroads of cancer signaling pathways.
  Bollaert E, de Rocca Serra A, Demoulin JB. Bollaert E, et al. Cell Mol Life Sci. 2019 Apr;76(8):1529-1539. doi: 10.1007/s00018-019-03012-9. Epub 2019 Jan 25. Cell Mol Life Sci. 2019. PMID: 30683982 Free PMC article. Review.
• HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.
  Klinge CM, Piell KM, Tooley CS, Rouchka EC. Klinge CM, et al. Sci Rep. 2019 Jul 1;9(1):9430. doi: 10.1038/s41598-019-45636-8. Sci Rep. 2019. PMID: 31263129 Free PMC article.
• Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer.
  Vanharanta S, Marney CB, Shu W, Valiente M, Zou Y, Mele A, Darnell RB, Massagué J. Vanharanta S, et al. Elife. 2014 Jun 4;3:e02734. doi: 10.7554/eLife.02734. Elife. 2014. PMID: 24898756 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal